DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy

Information source: NeurogesX
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infections

Intervention: Capsaicin Dermal Patch (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: NeurogesX


The purpose of the study is to gain initial information on the tolerability and feasibility of high-concentration capsaicin patches for the treatment of painful HIV-associated neuropathy, whether resulting from HIV disease and/or antiretroviral drug exposure. The study will also provide preliminary safety and efficacy information.

Clinical Details

Official title: An Open-Label Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy

Study design: Masking: Open Label, Primary Purpose: Treatment


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- Between 18 and 75 years of age.

- Documented evidence of HIV-1 infection.

- Painful HIV-associated neuropathy, whether resulting from HIV disease and/or

antiretroviral drug exposure, with primary symptoms of pain, burning or dysesthetic discomfort in both feet for at least 2 months prior to Screening Visit. AND:

- Diminished ankle reflexes (compared to the knee) or absent ankle reflexes,


- Distal diminution of either vibration sensation or pain or temperature sensation in

the legs.

- Either no neurotoxic antiretroviral (i. e., didanosine [ddI], zalcitabine [ddC], or

stavudine [d4T]) exposure for at least 8 weeks prior to Screening Visit, OR

- Currently on stable dose(s) of any of the neurotoxic antiretrovirals listed above for

at least 8 weeks prior to Screening Visit, without a foreseeable need to change doses or medications for duration of study.

- Screening Pain Sum Score of 12 to 36.

- Intact, unbroken skin over the painful area(s) to be treated.

- If taking chronic pain medications, be on a stable (not PRN) regimen for at least 7

days prior to Treatment Visit (Day 0) and willing to maintain medications at same stable dose(s) and schedule throughout the study.

- Be willing and able to use Roxicodone® (oxycodone) oral solution, if needed, to

relieve treatment-associated discomfort.

- Female subjects with child-bearing potential must have a negative urine or serum

pregnancy test, to be performed at the Screening Visit.

- All subjects must be willing to use effective methods of birth control and/or refrain

from participating in a conception process during the study and for 30 days following experimental drug exposure.

- Be willing and able to comply with protocol requirements for the duration of study

participation. (Such requirements include, but are not limited to: completing a daily pain diary, attending all study visits, and refraining from extensive travel during study participation.) Exclusion Criteria:

- Presence of acute, active opportunistic infection, except oral thrush; oral, genital,

or rectal herpes; and Mycobacterium avium bacteremia within 2 weeks prior to Screening Visit.

- Significant pain of an etiology other than painful HIV-associated neuropathy, for

example, compression-related neuropathies, e. g., spinal stenosis, or fibromyalgia or arthritis. Subjects must not have significant ongoing pain from other cause(s) that may interfere with judging HIV-associated neuropathy pain.

- Evidence of another contributing cause for peripheral neuropathy, e. g., diabetes

mellitus, hereditary neuropathy, vitamin B12 deficiency (B12 level less than or equal to 200 pg/mL) or less than 3 months of B12 supplementation prior to Screening Visit, or treatment within 90 days prior to Screening Visit with any drug that may have contributed to the sensory neuropathy.

- Any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral

nerve stimulator) for the treatment of neuropathic pain.

- Recent use (within 21 days preceding the Treatment Visit [Day 0]) of any topically

applied pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics (including Lidoderm®), steroids or capsaicin products on the painful areas.

- Treatment for acute opportunistic infections within 14 days before Treatment Visit

(Day 0). Maintenance treatment of cytomegalovirus (CMV) retinitis, Mycobacterium avium bacteremia, or cryptococcal meningitis is permitted.

- Current use of any investigational drug, or Class 1 anti-arrhythmic drugs (such as

tocainide and mexiletine).

- Hypersensitivity to capsaicin (i. e., chili peppers or OTC capsaicin products), local

anesthetics, Roxicodone or adhesives.

- Significant ongoing or untreated abnormalities in cardiac, renal, hepatic, or

pulmonary function that may interfere either with the ability to complete the study or the evaluation of adverse events.

- Currently have active malignant disease. Malignancies in remission that do not

require further treatment or Kaposi's sarcoma requiring local treatment only are allowed.

- High tolerance to opioids that precludes the ability to relieve treatment-associated

discomfort with Roxicodone® if needed, as judged by investigator.

- History or current problem with prescription drug, illicit substance, or alcohol

abuse from self report or as judged by investigator.

Locations and Contacts

NeurogesX Investigational Site, West Hollywood, California 90069, United States

NeurogesX Investigational Site, New York, New York 10029, United States

NeurogesX Investigational Site, Portland, Oregon 97209, United States

Additional Information

Last updated: September 12, 2007

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017